Gene editing therapies to permanently reduce cardiovascular disease
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $215.5M
Founded date: 2018
Investors 6
| Date | Name | Website |
| 21.02.2021 | Logos Capi... | logoscapit... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | F-Prime Ca... | fprimecapi... |
| - | RA Capital... | racap.com |
| - | Eight Road... | eightroads... |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 01.02.2021 | Series B | $94M | - |
| 12.06.2020 | - | $63M | - |
| 07.05.2019 | Series A | $58.5M | GV |
Mentions in press and media 22
| Date | Title | Description | Source |
| 19.12.2022 | How a gene-editing breakthrough from a Harvard lab saved the... | Alyssa, 13, was the first patient to receive a base-edited cell therapy to treat her leukemia in May... | businessin... |
| 12.10.2022 | Gene-editing companies are growing thanks to fast-paced scie... | Marianne Ayala/Insider This story is available exclusively to Insider subscribers. Become an Insider... | businessin... |
| 10.05.2022 | Verve gets New Zealand clearance to test base editing ther... | Two years ago, Intellia and Editas Medicine ventured into the field of science fiction whe... | endpts.com... |
| 10.11.2021 | Verve Therapeutics Announces Pipeline Progress and Reports T... | VERVE-101 Preclinical Data Announced at TIDES 2021 Demonstrated Potent, Durable PCSK9 Protein and LD... | marketscre... |
| 14.06.2021 | Verve Therapeutics Prepares $201 Million IPO | - | fprimecapi... |
| 28.05.2021 | Gene editing biotech Verve Therapeutics files for a $100 mil... | - | fprimecapi... |
| 01.02.2021 | Gene Editing Medicine Company Verve Therapeutics Raises $94 ... | Verve Therapeutics — a biotech company pioneering gene-editing medicines to treat cardiovascular dis... | pulse2.com... |
| 19.01.2021 | Verve Therapeutics Closes $94 Million Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a biotech company pioneering gene editing med... | citybizlis... |
| 19.01.2021 | Verve Therapeutics Secures $94 Million in Series B Financing... | - | fprimecapi... |
| 19.01.2021 | Verve Therapeutics Secures $94M in Series B Financing | Verve Therapeutics, a Cambridge, Mass.-based biotech company pioneering gene editing medicines to tr... | finsmes.co... |
Show more